Shilpa Medicare Limited will host an earnings conference call on Wednesday, August 05, 2026, at 16:00 hrs IST to discuss its financial results for the first quarter ended June 30, 2026. The announcement was made pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This scheduled briefing provides investors and analysts with a direct channel to review the company’s performance in Q1FY27.

The company disclosed the schedule via a filing with the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE). Ritu Tiwary, Company Secretary, signed the intimation dated July 29, 2026. A copy of the intimation is available on the company’s investor relations webpage. The earnings call serves as the primary mechanism for management to address queries regarding the recent quarterly performance.

Participants can access the conference call through multiple channels. Universal access numbers are provided for domestic and international callers, ensuring accessibility from all networks and countries. Additionally, a DiamondPass™ link is available for participants who wish to join without wait times. Investors are requested to dial in 10 minutes before the scheduled start time to ensure seamless entry.

Shilpa Medicare Limited operates as an integrated pharmaceutical group with interests in niche Oncology and Non-oncology APIs, Peptides, Polymers, and differentiated finished dosage formulations. The company also offers end-to-end CDMO services to global pharmaceutical companies. Its operations are supported by four R&D units and seven manufacturing facilities. Monish Shah is the contact person for further details regarding the company’s business segments.

Shilpa Medicare Limited has appointed Dr. Uday N. Harle as the Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, its wholly owned subsidiary. The appointment takes effect on August 03, 2026, marking a strategic leadership addition to the company's biologics division. This move aims to leverage Dr. Harle's extensive experience in the global biopharmaceutical sector to drive growth and operational efficiency within the subsidiary.

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026. Ritu Tiwary, Company Secretary and Compliance Officer, signed the disclosure on August 03, 2026. The appointment was communicated to the BSE Limited and National Stock Exchange of India Ltd.

Dr. Uday N. Harle brings approximately 24 years of experience in the global biopharmaceutical industry. His expertise includes over 18 years in biologics and biosimilars and more than 14 years in leadership roles across research and development, clinical development, regulatory affairs, manufacturing, commercialization, and business management. He holds a Ph.D. in Pharmaceutical Sciences from Nagpur University (RTM Nagpur University) and a Master of Science in Pharmacy. Additionally, he holds Post-Graduate Diplomas in Business Management and Marketing Management from IGNOU.

Appointment Overview

The key details of Dr. Harle's appointment are summarised below:

Professional Background

Dr. Harle's most recent assignment was as Chief Business Officer at Artemis Medicare Services Limited and Premedium Pharma (Apollo Group). Prior to this role, he served as Assistant Vice President & Global Head - Clinical Development at Amneal Group / Kashiv Biosciences. His career also includes tenure as Global Head - Clinical Development at Abbott and Associate Director & R&D Head at Ferring Pharmaceuticals. He has held key positions with Bharat Serums & Vaccines, Sun Pharma, and other leading pharmaceutical organizations.

His expertise spans the entire biologics value chain, including portfolio strategy, research and development, CMC, clinical development, regulatory approvals, manufacturing, commercialization, CDMO partnerships, and P&L management. He possesses significant global regulatory experience, having worked extensively with agencies including the USFDA, EMA, MHRA, Health Canada, and CDSCO. Dr. Harle has contributed to the development of more than 10 biosimilars and over 5 novel biologics, including multiple IND and BLA submissions. His experience also covers peptides, recombinant proteins, cell therapies (including CAR-T), and medical devices.

Dr. Harle has authored approximately 40 scientific publications, published 2 books, and holds 2 patents. He has received several industry awards recognizing his contributions and excellence in biopharmaceutical research and development.